Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
about
Biology of RANK, RANKL, and osteoprotegerinFunctions of the osteocyte network in the regulation of bone massRelationship between serum RANKL and RANKL in boneThe LIM protein LIMD1 influences osteoblast differentiation and functionShort-term bone loss in HIV-infected premenopausal womenOsteoporosis: the current status of mesenchymal stem cell-based therapy.No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one yearBone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives.Proteomics in bone research.Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women.Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone lossFollicle-stimulating hormone promotes RANK expression on human monocytesPlasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor.Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.Effect of Ultra-marathon (308 km) Race on Bone Metabolism and Cartilage Damage Biomarkers.Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease.Multifactorial analysis of risk factors for reduced bone mineral density among postmenopausal womenHormone concentrations throughout uncomplicated pregnancies: a longitudinal study.Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblastsRelationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women.Aromatase inhibitor treatment for breast cancer: short-term effect on bone healthPlatelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand diseaseCirculating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.Functions of RANKL/RANK/OPG in bone modeling and remodeling.RANKL is a mediator of bone resorption in idiopathic hypercalciuria.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Vitamin K, circulating cytokines, and bone mineral density in older men and women.Human iPSC-derived osteoblasts and osteoclasts together promote bone regeneration in 3D biomaterials.Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.Altered bone metabolism in inflammatory disease: role for nutrition.Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy.Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.
P2860
Q21195419-3ABDE5B7-C293-4E85-AFAE-A92D6605B957Q27002647-A3ED338A-CEF9-4FCA-8374-936B03F718E6Q28245828-C8DB9E2B-4536-4CAB-833D-C376E3D7EFE5Q28586398-19748A7C-BE3C-4EEC-A4F2-06D9F9E2DA5BQ33618567-00BEFD29-1F46-45AF-B191-F5D4DAF42DE0Q33631498-536B69AF-92EF-4D7B-A4D6-72C5951E0314Q33638583-6B5735C5-9DC1-457C-A1A8-50672BFFB5ECQ33702810-0466132F-87F5-4731-B3C1-D5ED649C490AQ33767411-12595490-2C47-47C8-9C75-E0B4F9BB1322Q33937903-73F2CE70-112A-488D-BC10-363A4F88BCABQ34440102-5FFFC5B3-6AC4-4E43-A0CD-56E0D89405EEQ34494324-078F65CE-B63C-41DD-A406-6D19AC6D4ADEQ34828137-A72D8E49-EDE0-4157-854E-14B9E17F4F1AQ34960867-87635DD2-CD3A-4AF3-BD10-078659D6FF00Q35623636-2E411CFF-0E2B-4EDF-90F5-73E6BC97F7B6Q35658848-0A558CCD-B44A-41FA-AF54-1A2D079326CFQ35742069-442AE1DB-2E74-4FEB-A736-7C10766F56DBQ35843620-D0CAC71B-2A98-41DB-AD91-E4B0E15A8D5FQ35885233-F879451C-74DE-44A4-9EAC-EE5DD7277D2BQ35886675-70CFA963-D59C-44F1-9070-7EECC3B38EBCQ35990478-FBAC91E6-5FCB-499C-BD17-DBB7EB40D8A2Q36067573-23804400-E7B5-4AA5-88AA-C8C30EF2C4F0Q36293557-6E24033E-5408-48AF-B5FD-97E00C6F9E6EQ36361444-6DAF4801-5314-48AC-8D0B-22CDF885E909Q36452858-C471C15C-BA1F-449A-84BA-197244AE9F74Q36559664-859F00A2-EC67-4B52-9EE4-1F514CD29078Q36641523-6DD5E0F3-DE90-400B-AFD9-93CE78B9FE20Q36661106-E1F2BA6E-18B2-4E75-B66A-2F72F411206CQ36700779-A80C90E1-E856-442B-8DDE-90C90AADEE5AQ36843360-76E2CE2C-65EA-42C9-86E6-00EE793701CCQ36860987-237DF0EE-5F43-4960-92E0-AEB489B88834Q36868914-545B9EA0-F717-4912-99F3-EA7DC1DB49FEQ36938328-8842941B-C91D-4336-9784-9C5E7FBCFF55Q36973979-10E9FF8A-DB8B-4E70-B469-55448B57F08DQ37097170-C92E89C5-1640-40FA-A09E-89F9CFA43ED4Q37138659-4A934D60-781F-47F7-B839-C4F3A8DE7E9BQ37155255-29F2C9AA-337D-4152-B117-C4D6F84057F7Q37176381-B6E6D405-3DDD-43DE-9F37-BCA05433C5B5Q37344527-F234EF21-4DE4-41CA-90F6-EE3994538F49Q37396629-23175E2C-1E3C-40F6-8737-F464308B51BE
P2860
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@ast
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@en
type
label
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@ast
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@en
prefLabel
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@ast
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@en
P356
P1476
Circulating osteoprotegerin an ...... bolic bone disease assessment.
@en
P2093
Angela Rogers
Richard Eastell
P304
P356
10.1210/JC.2005-0794
P407
P577
2005-08-16T00:00:00Z